Peficitinib - Astellas Pharma

Drug Profile

Peficitinib - Astellas Pharma

Alternative Names: ASP-015K; ASP-015K hydrobromide; JNJ-54781532; Peficitinib hydrobromide

Latest Information Update: 05 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Adamantanes; Amides; Antipsoriatics; Antirheumatics; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Rheumatoid arthritis
  • Discontinued Plaque psoriasis; Transplant rejection; Ulcerative colitis

Most Recent Events

  • 06 Sep 2018 Astellas Pharma plans a phase III trial for Rheumatoid arthritis (Combination therapy) in September 2018 (NCT03660059)
  • 24 Jun 2018 Biomarkers information updated
  • 05 Jun 2018 Preregistration for Rheumatoid arthritis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top